Health Problems
Acute myeloid leukaemia (AML)
Acute myeloid leukaemia (AML) is a cancer of the blood and bone marrow, characterised by a rapid and abnormal production of immature myeloid cells. These cells disrupt the normal formation of red blood cells, white blood cells and platelets. An AML diagnosis is generally based on an analysis of the bone marrow, often by means of a biopsy puncture.
This condition requires the intervention of trained haematologists who are experienced in managing pathologies of this kind.
Patients with acute myeloid leukaemia are treated at our specialised unit with 18 single rooms where a specialised medical and paramedical staff that includes nurses, physiotherapists, dieticians and psychologists work closely together to provide the best possible care.
After an in-depth evaluation we propose an individualised course of chemotherapy to eliminate the leukemic cells. Depending on the type of chemotherapy, some patients may have to be hospitalised until the end of the period of aplasia so as to ensure rapid access to care and a controlled environment to minimise the risk of infections. For others, less intensivc chemotherapy permits early discharge followed by external consultations to monitor progress.
After remission, consolidation treatment is envisaged that may include further cycles of chemotherapy or a bone marrow transplant.
If your doctor diagnoses or suspects an acute leukaemia, please contact our Haematology Department immediately.
You will be quickly directed to a consultation at which our specialised team will assess your condition and draw up an appropriate treatment plan. In some cases immediate hospitalisation may be necessary to begin tests and the appropriate medical intervention.
Close medical follow-up and strict adherence to the programme of prescribed medication are essential to your care. Maintain a healthy lifestyle while remaining physically active and avoiding situations with a risk of infection to optimise your recovery
We provide access to a number of international medical trials that enable patients who so wish to benefit from innovative treatment.
https://www.bordet.be/en/search/trials-full
The Jules Bordet Institute is a member of ERN EURACAN, the European network of centres of expertise on rare tumours, for the treatment of acute promyelocytic leukaemia.
Andreozzi Fabio
Buntinx Sarah
Lewalle Philippe
Salaroli Adriano
Spilleboudt Chloé
Wittnebel Sebastian